dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology 
Welcome,         Profile    Billing    Logout  

3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
AVM0703, NCT04366115: Evaluating for Treatment of COVID-19 or Influenza-mediated ARDS

Not yet recruiting
1
16
NA
AVM0703, Suprapharmacologic dexamethasone sodium phosphate, Placebo
AVM Biotechnology LLC, Medpace, Inc.
ARDS, Covid19, Influenza, Human
12/24
03/25
NCT05974410: Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Available
N/A
NA
AVM0703, Hydrocortisone, Proton pump inhibitor
AVM Biotechnology Inc
Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Breast Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Acute Leukemia, Pancreatic Cancer, Spindle Cell Sarcoma, Cancer, Tumor, Solid, Tumor, Brain
 
 

Download Options